Market Overview

Morgan Stanley Sees Possible Good Things Ahead For Medtronic

Share:
Related MDT
Argus Gives Medtronic Improved Prognosis, Expects Nearly 10% Future Growth
Benzinga's Top Upgrades, Downgrades For December 12, 2017
Meet The 'Editor' That Tells You What Your New Product Needs (Investor's Business Daily)

In a report published Friday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Medtronic (NYSE: MDT).

In the report, Morgan Stanley noted, “Reveal Linq may the sleeper product of HRS 2014. First generation Reveal was a tertiary product worth only ~$50-60 million in sales, but the second gen device is different. Reveal Linq makes major strides in innovation and telemetry and comes at a 20% price premium. With unusually strong clinical feedback, this device could open up a renewed global market for cardiac monitoring worth $500 million or more.”

Medtronic closed on Thursday at $59.43.

Latest Ratings for MDT

DateFirmActionFromTo
Jan 2018Evercore ISI GroupInitiates Coverage OnOutperform
Jan 2018Bank of AmericaUpgradesNeutralBuy
Dec 2017ArgusUpgradesHoldBuy

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (MDT)

View Comments and Join the Discussion!